Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Fresenius Kabi Launches Tyenne®, the First Tocilizumab Biosimilar
Fresenius Kabi has launched its tocilizumab biosimilar, Tyenne®, which references Actemra®** (tocilizumab), making it the first and only tocilizumab biosimilar available in Canada.
Hansoh Pharmaceutical Group Introduces Breakthrough B7-H3-Targeted Antibody-Drug Conjugate (ADC) HS-20093
Hansoh Pharmaceutical Group has announced that its B7-H3-targeted antibody-drug conjugate (ADC), HS-20093, has received approval for breakthrough therapy designation from the National Medical Products Administration (NMPA) of China.
Ultragenyx Pharmaceutical Developed First-of-its-kind Setrusumab (UX143) for Osteogenesis Imperfecta
Ultragenyx Pharmaceutical has developed setrusumab (UX143), a groundbreaking treatment aimed at reducing the fracture risk associated with osteogenesis imperfecta (OI) Types I, III, or IV in patients aged 2 years and older.
Boehringer Ingelheim Discovered Novel Survodutide for the Treatment of Advanced Fibrosis
Boehringer Ingelheim has identified a novel treatment known as survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist, for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis (stages 2 or 3).
Arrowhead Pharmaceuticals Develops Novel Plozasiran
Arrowhead Pharmaceuticals has developed plozasiran (formerly ARO-APOC3), a novel investigational therapy designed to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
Genentech Unveils First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech has unveiled Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), making it the first and only PD-(L)1 inhibitor available as a subcutaneous (SC) injection in the United States.
Johnson & Johnson Develops Novel RYBREVANT® for EGFR-Mutated Advanced Lung Cancer
Johnson & Johnson has introduced a groundbreaking therapy, RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib), for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or exon 21 L858R substitution mutations.
Daiichi Sankyo Introduces First-of-its-kind ENHERTU® for Metastatic Breast Cancer
Daiichi Sankyo has introduced ENHERTU®, a groundbreaking treatment option for certain patients with HER2 low or HER2 ultralow metastatic breast cancer. ENHERTU is a leading antibody-drug conjugate (ADC) in oncology portfolio, designed using proprietary DXd ADC technology.
Duke-NUS Medical School Discovered Breakthrough Treatment for Neurodevelopmental Disorders
Researchers at Duke-NUS Medical School and the Mechanobiology Institute (MBI) at the National University of Singapore (NUS) have uncovered a novel pathway that can awaken dormant neural stem cells, paving the way for potential new therapies for neurodevelopmental disorders such
Novartis Discovered First-of-its-Kind Fabhalta (iptacopan) Immunoglobulin A Nephropathy
Novartis has introduced Fabhalta (iptacopan), a first-of-its-kind treatment designed to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Fabhalta specifically targets the alternative complement pathway
